

## **Novel linker and bioconjugation technology for the production of next generation ADC candidates with improved Therapeutic Index (TI)**

Bernd Schlereth

Chief Development Officer, Araris Biotech AG, 8804 Au, Switzerland  
bschlereth@ararisbiotech.com

The Araris ADC technology allows for enzymatic linker-payload conjugation to 'off-the-shelf' antibodies in a single step without the need for antibody engineering prior to payload conjugation. The conjugation is site-specific and takes place at the conserved glutamine 295 (Q295) at the Fc-part of antibodies through the enzyme microbial transglutaminase (MTG). The resulting ADCs are homogenous, stable, highly potent and well tolerated.

Araris will present two ADC case studies (one for liquid tumor and one for solid tumor indications) and benchmark those Araris ADCs head-to-head to ADCs that are already on the market.